Tag Archives: PFIZER SAYS ANTIVIRAL PILL CUTS RISK OF SEVERE COVID-19 BY 89%

A trial of Pfizer’s experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday. The results appear to surpass those seen with Merck’s pill, molnupiravir, which was shown last month to halve the likelihood …

Read More »